453 related articles for article (PubMed ID: 31986471)
1. Reducing the progression of Alzheimer's disease in Down syndrome patients with micro-dose lithium.
Priebe GA; Kanzawa MM
Med Hypotheses; 2020 Apr; 137():109573. PubMed ID: 31986471
[TBL] [Abstract][Full Text] [Related]
2. SLOH, a carbazole-based fluorophore, mitigates neuropathology and behavioral impairment in the triple-transgenic mouse model of Alzheimer's disease.
Wu X; Kosaraju J; Zhou W; Tam KY
Neuropharmacology; 2018 Mar; 131():351-363. PubMed ID: 29309769
[TBL] [Abstract][Full Text] [Related]
3. Beneficial synergistic effects of microdose lithium with pyrroloquinoline quinone in an Alzheimer's disease mouse model.
Zhao L; Gong N; Liu M; Pan X; Sang S; Sun X; Yu Z; Fang Q; Zhao N; Fei G; Jin L; Zhong C; Xu T
Neurobiol Aging; 2014 Dec; 35(12):2736-2745. PubMed ID: 25018109
[TBL] [Abstract][Full Text] [Related]
4. Selenomethionine Mitigates Cognitive Decline by Targeting Both Tau Hyperphosphorylation and Autophagic Clearance in an Alzheimer's Disease Mouse Model.
Zhang ZH; Wu QY; Zheng R; Chen C; Chen Y; Liu Q; Hoffmann PR; Ni JZ; Song GL
J Neurosci; 2017 Mar; 37(9):2449-2462. PubMed ID: 28137967
[TBL] [Abstract][Full Text] [Related]
5. Signalling Pathways Implicated in Alzheimer's Disease Neurodegeneration in Individuals with and without Down Syndrome.
Martínez-Cué C; Rueda N
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962300
[TBL] [Abstract][Full Text] [Related]
6. Does lithium prevent Alzheimer's disease?
Forlenza OV; de Paula VJ; Machado-Vieira R; Diniz BS; Gattaz WF
Drugs Aging; 2012 May; 29(5):335-42. PubMed ID: 22500970
[TBL] [Abstract][Full Text] [Related]
7. Microvascular changes in Down syndrome with Alzheimer's-type pathology: Insights into a potential vascular mechanism for Down syndrome and Alzheimer's disease.
Drachman DA; Smith TW; Alkamachi B; Kane K
Alzheimers Dement; 2017 Dec; 13(12):1389-1396. PubMed ID: 28627379
[TBL] [Abstract][Full Text] [Related]
8. Common genetic signatures of Alzheimer's disease in Down Syndrome.
Sharma A; Chunduri A; Gopu A; Shatrowsky C; Crusio WE; Delprato A
F1000Res; 2020; 9():1299. PubMed ID: 33633844
[No Abstract] [Full Text] [Related]
9. Down syndrome individuals with Alzheimer's disease have a distinct neuroinflammatory phenotype compared to sporadic Alzheimer's disease.
Wilcock DM; Hurban J; Helman AM; Sudduth TL; McCarty KL; Beckett TL; Ferrell JC; Murphy MP; Abner EL; Schmitt FA; Head E
Neurobiol Aging; 2015 Sep; 36(9):2468-74. PubMed ID: 26103884
[TBL] [Abstract][Full Text] [Related]
10. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study.
Hampel H; Ewers M; Bürger K; Annas P; Mörtberg A; Bogstedt A; Frölich L; Schröder J; Schönknecht P; Riepe MW; Kraft I; Gasser T; Leyhe T; Möller HJ; Kurz A; Basun H
J Clin Psychiatry; 2009 Jun; 70(6):922-31. PubMed ID: 19573486
[TBL] [Abstract][Full Text] [Related]
11. Alzheimer's disease in people with Down's syndrome: the prospects for and the challenges of developing preventative treatments.
Castro P; Zaman S; Holland A
J Neurol; 2017 Apr; 264(4):804-813. PubMed ID: 27778163
[TBL] [Abstract][Full Text] [Related]
12. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease.
Onishi T; Iwashita H; Uno Y; Kunitomo J; Saitoh M; Kimura E; Fujita H; Uchiyama N; Kori M; Takizawa M
J Neurochem; 2011 Dec; 119(6):1330-40. PubMed ID: 21992552
[TBL] [Abstract][Full Text] [Related]
13. Lithium down-regulates tau in cultured cortical neurons: a possible mechanism of neuroprotection.
Rametti A; Esclaire F; Yardin C; Cogné N; Terro F
Neurosci Lett; 2008 Mar; 434(1):93-8. PubMed ID: 18289787
[TBL] [Abstract][Full Text] [Related]
14. Nanolithium, a New Treatment Approach to Alzheimer's Disease: A Review of Existing Evidence and Clinical Perspectives.
Guilliot S; Wilson EN; Touchon J; Soto ME
J Prev Alzheimers Dis; 2024; 11(2):428-434. PubMed ID: 38374749
[TBL] [Abstract][Full Text] [Related]
15. Neurons derived from sporadic Alzheimer's disease iPSCs reveal elevated TAU hyperphosphorylation, increased amyloid levels, and GSK3B activation.
Ochalek A; Mihalik B; Avci HX; Chandrasekaran A; Téglási A; Bock I; Giudice ML; Táncos Z; Molnár K; László L; Nielsen JE; Holst B; Freude K; Hyttel P; Kobolák J; Dinnyés A
Alzheimers Res Ther; 2017 Dec; 9(1):90. PubMed ID: 29191219
[TBL] [Abstract][Full Text] [Related]
16. Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer's disease: protection against and interruption of progression of amyloid and tau pathology and cognitive decline.
Clausen A; Xu X; Bi X; Baudry M
J Alzheimers Dis; 2012; 30(1):183-208. PubMed ID: 22406441
[TBL] [Abstract][Full Text] [Related]
17. Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles.
Caccamo A; Oddo S; Tran LX; LaFerla FM
Am J Pathol; 2007 May; 170(5):1669-75. PubMed ID: 17456772
[TBL] [Abstract][Full Text] [Related]
18. Isorhynchophylline treatment improves the amyloid-β-induced cognitive impairment in rats via inhibition of neuronal apoptosis and tau protein hyperphosphorylation.
Xian YF; Mao QQ; Wu JC; Su ZR; Chen JN; Lai XP; Ip SP; Lin ZX
J Alzheimers Dis; 2014; 39(2):331-46. PubMed ID: 24164737
[TBL] [Abstract][Full Text] [Related]
19. Ebselen ameliorates β-amyloid pathology, tau pathology, and cognitive impairment in triple-transgenic Alzheimer's disease mice.
Xie Y; Tan Y; Zheng Y; Du X; Liu Q
J Biol Inorg Chem; 2017 Aug; 22(6):851-865. PubMed ID: 28502066
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
